IMIM - Institut Hospital del Mar d'Investigacions Mèdiques IMIM - Institut Hospital del Mar d'Investigacions Mèdiques

News

  • 23/08/2022 - General information

    Usefulness of breast biopsy guided by contrast-enhanced mammography is validated

    A team from Hospital del Mar and the Hospital del Mar Medical Research Institute has validated the technique involving breast biopsy guided by contrast mammography to visualise suspicious lesions that cannot be observed via ultrasound or mammography. After analysing data from tests performed on 64 women, they have been able to verify that this technique offers the same or better results than the other diagnostic tool used in these cases, magnetic resonance imaging (MRI). The results have been published in the journal European Radiology. In the cases studied, contrast mammography-guided breast biopsy was successful in 95.4% of cases. In only three tests was the visibility of the findings not as expected. In comparison, MRI has a success rate of between 87% and 98%.

    Més informació "Usefulness of breast biopsy guided by contrast-enhanced mammography is validated"

  • 12/07/2022 - General information

    A project led by Dr. Toni Celià-Terrassa receives financial support from the "la Caixa" Foundation

    This is one of the fifteen biomedical projects selected in the CaixaResearch Validate call. In this case, the study led by the researcher from the Hospital del Mar Medical Research Institute seeks effective immunotherapy treatment for breast tumours. The "la Caixa" Foundation is supporting 15 leading biomedical research projects in Spain and Portugal in the CaixaResearch Validate 2022 call. These are early-stage projects that the organisation wants to support to accelerate their arrival on the market, thereby helping them reach patients who may need them. Among those selected is a project led by Dr. Toni Celià-Terrassa, who heads up the Cancer Stem Cells and Metastasis Dynamics laboratory at the Hospital del Mar Medical Research Institute (IMIM-Hospital del Mar).

    Més informació "A project led by Dr. Toni Celià-Terrassa receives financial support from the "la Caixa" Foundation"

  • 17/06/2022 - Institutional news

    Solidarity boosts lung cancer research

    The Friends of the Hospital del Mar Foundation and APRO, the Association for Oncological Research, have awarded Dr. Edurne Arriola more than 8,000 euros to boost immunotherapy and lung cancer research being carried out at Hospital del Mar and the Hospital del Mar Medical Research Institute. Lung cancer research at Hospital del Mar and the Hospital del Mar Medical Research Institute has received a new boost thanks to the Friends of the Hospital del Mar Foundation and APRO, the Association for Oncological Research. The two organisations have managed to raise 8,000 euros, which will be used to support the work of researchers in this field.

    Més informació "Solidarity boosts lung cancer research"

  • 17/03/2022 - Press release

    Radical increase in the effectiveness of breast cancer immunotherapy

    Researchers at the Hospital del Mar Medical Research Institute and Hospital del Mar have transformed immunotherapy-resistant tumours into tumours that respond to this treatment, achieving cures in animal models through an innovative therapeutic strategy in triple-negative breast cancer, the most aggressive subtype. Researchers have discovered the essential role of a new factor, LCOR, in enabling cancer cells to present tumour antigens on their surfaces. These antigens allow the immune system to recognise the tumour, an essential step if immunotherapy treatment is to succeed. On the other hand, they have shown that cancer stem cells have very low levels of LCOR, making them invisible to the immune system and therefore resistant to treatment. The work that has just been published used an innovative experimental messenger RNA system, similar to the technology used for COVID-19 vaccines, to produce LCOR in tumour cells. In this way, the resistant tumour cells of triple-negative cancer become visible and sensitive to the immune system. This approach is also being investigated in other breast cancer subtypes

    Més informació "Radical increase in the effectiveness of breast cancer immunotherapy"

  • 17/02/2022 - General information

    M. Chiara Giorgetti Award for a Hospital del Mar Medical Research Institute project

    An IMIM-Hospital del Mar research project aimed at analyzing the mechanisms that generate resistance to immunotherapy treatment in metastatic breast cancer has been selected by the Metastatic Breast Cancer Association in the third edition of this award. The project, headed by doctors Toni Celià-Terrassa and Joan Albanell, will receive 100,000 euros for its development. This afternoon saw the presentation of the III M. Chiara Giorgetti Award for research into metastatic breast cancer. This year it recognises a project from the Hospital del Mar Medical Research Institute (IMIM-Hospital del Mar), led by doctors Toni Celià-Terrassa and Joan Albanell. The award is promoted by the Metastatic Breast Cancer patients' association and involves a prize of 100,000 euros, 25,000 euros of which are provided by the AMAMA association.

    Més informació "M. Chiara Giorgetti Award for a Hospital del Mar Medical Research Institute project"

  • 08/02/2022 - Press release

    Colorectal cancers raise defensive barrier in response to chemotherapy

    Drugs which are commonly-used as the first line of treatment for colorectal cancer cause the tumour cells to oversecrete proteins known as mucins, according to a new study published today in the journal eLife. The proteins alter the mucous layer, forming a physical barrier that prevents drugs from reaching their intended target. Using different techniques involving genetic manipulation and the use of chemical inhibitors, the research team were able to experimentally regulate mucin secretion in cancer cell lines and patient-derived organoids, paving the way for the development of future treatments that can be used alongside chemotherapy to target drug-resistant forms of colorectal cancer. The experiments also revealed potential new biomarkers for the prognosis of the disease.

    Més informació "Colorectal cancers raise defensive barrier in response to chemotherapy"

  • 04/02/2022 - Institutional news

    The Science and Innovation Minister gets a first-hand look at cancer research at the IMIM-Hospital del Mar

    This morning, Minister Diana Morant visited the facilities of the Hospital del Mar Medical Research Institute, accompanied by the manager of the Parc de Salut Mar, Dr. Olga Pané, the director of the IMIM, Dr. Joaquín Arribas, and the director of the IMIM's Cancer Research Programme, Dr. Juan Albanell. During the event, she visited the laboratory of the New Molecular Targets in Cancer Research Group and met with the heads of the IMIM's cancer research groups.

    Més informació "The Science and Innovation Minister gets a first-hand look at cancer research at the IMIM-Hospital del Mar"

  • 31/01/2022 - General information

    Research led by the Hospital del Mar Medical Research Institute selected in the first edition of the Cancer Innova project.

    Glioblastoma and oral drugs for various types of cancer are among the targets of the projects for the first phase, selected from among more than a hundred proposals, due to their clinical and industrial relevance The project "PARP2: a new therapeutic target in c-myc-driven tumours", headed up by Dr. José Yélamos, coordinator of the Poly (ADP-ribose) polymerase research group at the Hospital del Mar Medical Research Institute (IMIM) and the Immunology Service at Hospital del Mar, has been selected in the first edition of the Cancer Innova initiative, a consortium comprising the Kaertor Foundation and the Spanish Association Against Cancer in collaboration with the pharmaceutical companies Janssen and Lilly, which is supported by the Galician regional government. On this occasion, 110 proposals from eight countries were submitted, of which just five were selected based on their high clinical and industrial impact.

    Més informació "Research led by the Hospital del Mar Medical Research Institute selected in the first edition of the Cancer Innova project."

  • 27/01/2022 - Press release

    New diagnostic marker for pancreatic cancer identified

    This is a new valid marker for diagnosing this type of tumour, one of the cancers with the worst prognosis. It is, in fact, the third leading cause of cancer death in developed countries. The study, published in the journal eBioMedicine, was led by researchers from the Hospital del Mar Medical Research Institute and IBB-CSIC-IDIBAPS. Their results point to a protein present in tumour cells as an indicator of pancreatic cancer in early stages of the disease. This marker can be detected through a simple blood test, facilitating its application in clinical practice. A team of researchers from the Hospital del Mar Medical Research Institute (IMIM-Hospital del Mar) and IIBB-CSIC-IDIBAPS have identified a new viable early diagnostic marker for the most common type of pancreatic cancer, pancreatic ductal adenocarcinoma. The study has been published in the journal eBioMedicine, from The Lancet group, and may represent an important step in the early detection and treatment of this type of tumour, with one of the worst prognoses. Doctors and researchers from the Digestology and Medical Oncology Departments at Hospital del Mar, as well as from the Spanish National Cancer Research Centre (Centro Nacional de Investigaciones Oncológicas; CNIO), the Ramón y Cajal Institute for Health Research (Instituto Ramón y Cajal de Investigación Sanitaria; IRYCIS) and CIBER also collaborated in the study.

    Més informació "New diagnostic marker for pancreatic cancer identified"

  • 26/01/2022 - General information

    Partial intraoperative radiotherapy in breast cancer, more highly rated by patients

    The technique achieves good results in terms of toxicity, the preservation of the physical appearance and patient ratings when used for partial breast irradiation compared to its use in combination with large doses of fractionated whole-breast irradiation. Patients with early-stage breast cancer more positively evaluate treatment with partial intraoperative radiotherapy of the breast than the approach that uses the same technique in combination with whole-breast irradiation divided into large doses. This is highlighted in a study published in the journal Clinical and Translational Oncology, led by the Radiation Oncology Service and the Functional Breast Pathology Unit at Hospital del Mar as well as researchers in the Radiation Oncology Research Group at the Hospital del Mar Medical Research Institute.

    Més informació "Partial intraoperative radiotherapy in breast cancer, more highly rated by patients"

© Institut Hospital del Mar
d'Investigacions Mèdiques
Legal Notice and Privacy Policy | Cookie Policy | Site Index | Accessibility | Find Us | Contact